All In Biotech

NDA 022560 · Apil

Atelvia

Risedronate Sodium · Oral

Last checked: Nov 20, 2026Latest source record: Feb 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Oct 8, 2010

Approved uses

1

Original approval plus efficacy supplements

Registered trials

95

42 Phase 3, 2 recruiting

FAERS reports

13,245

11,961 serious, 1,836 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 3, 2026.

Risedronate sodium is a bisphosphonate in a delayed-release formulation and is indicated for treatment of postmenopausal osteoporosis ( 1.1 ) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use ( 1.2 ) 1.1 Postmenopausal Osteoporosis Risedronate sodium delayed-release is indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women, risedronate sodium has been shown to reduce the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures [ see Clinical Studies (14.1) ] . 1.2 Important Limitations of Use The optimal duration of use has not been determined. The safety and effectiveness of Risedronate sodium delayed-release for the treatment of osteoporosis are based on clinical data of one year duration. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.

Mechanism: Risedronate has an affinity for hydroxyapatite crystals in bone and acts as an antiresorptive agent. At the cellular level, risedronate inhibits osteoclasts. The osteoclasts adhere normally to the bone surface, but show evidence of reduced active resorption (for example, lack of ruffled border). Histomorphometry in rats, dogs, and minipigs showed that risedronate treatment reduces bone turnover (activation frequency, that is, the rate at which bone remodeling sites are activated) and bone resorption at remodeling sites.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ATELVIA · RISEDRONATE SODIUM 35MG · TABLET, DELAYED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Risedronate" as an intervention, any sponsor and status, largest first.

All 95 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pain2,586
  • drug ineffective2,547
  • off label use2,520
  • vomiting2,310
  • drug hypersensitivity2,305
  • dyspnoea2,272
  • arthralgia2,259
  • pneumonia2,083
  • fatigue1,975
  • rheumatoid arthritis1,904
  • wheezing1,886
  • asthma1,857

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004228
2005261
2006138
2007247
2008316
2009217
2010169
2011220
2012313
2013168
2014136
2015207
2016286
2017196
2018315
2019524
20201,019
20211,143
20221,435
20231,435
20241,666
20251,640
2026966

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Atelvia (Risedronate Sodium)

2024 spending

$172K

Beneficiaries

92

382 claims

Per beneficiary

$1,867

$62.32 per unit

View as table
YearSpending
2020$606,173
2021$398,804
2022$292,726
2023$223,816
2024$171,764

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 449 on PubMed

Sponsor: Apil

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.